Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Cost Plus, Inc. (“Cost Plus” or the “Company”) (NASDAQ: CPWM) for potential breaches of fiduciary duties in connection with their conduct related to the sale of the Company to Bed Bath and Beyond Inc. (NASDAQ: BBBY) in an all-cash deal valued at about $494 million. Under the terms of the proposed transaction, Cost Plus stockholders will receive $22.00 in cash for each share of Cost Plus common stock they own. The proposed transaction is structured as a tender offer and may be effectuated without a shareholder vote.
Request more information now by clicking here: www.faruqilaw.com/CPWM. There is no cost or obligation to you.
Whether the Board of Directors of Cost Plus breached their fiduciary duties to the Company’s stockholders by failing to conduct an adequate and fair sales process prior to agreeing to this proposed transaction, whether the proposed transaction undervalues Cost Plus shares and by how much this proposed transaction undervalues the Company to the detriment of Cost Plus shareholders are the key focus of this investigation.
Faruqi & Faruqi, LLP is a national law firm which represents investors and individuals in class action litigation. The firm is focused on providing exemplary legal services in complex litigation in the areas of securities, shareholder, antitrust and consumer litigation, throughout all phases of litigation. The firm has an experienced trial team which has achieved significant victories on behalf of the firm’s clients.If you own common stock in Cost Plus and wish to obtain additional information and protect your investments free of charge, please visit us at www.faruqilaw.com/CPWM or contact Juan E. Monteverde, Esq. either via e-mail at email@example.com or by telephone at (877) 247-4292 or (212) 983-9330. Attorney Advertising. (C) 2012 Faruqi & Faruqi, LLP. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We are happy to discuss your particular case.